Kodiak Sciences Inc.

KOD Healthcare Biotechnology

In the quarter to June 2026, EPS fell 1.94% and free cash flow fell 33.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

85.75 2.37 −2.69%
Market cap
$5.5B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(207.92%) (149.49%) (208.80%) (368.37%)
ROA
(73.58%) (66.94%) (76.39%) (94.25%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(177.85%) (90.35%) (111.33%) (154.24%)
Free Cash Flow per Share
(2.41) (2.57) (2.39) (2.55)
Free Cash Flow
(127.29) (136.51) (148.12) (159.90)
Other line items

Show all line items

Columns are period end dates